Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clonazepam · 1 trial · 1 indication
Summary of video EEG number of spikes and sharp waves. Over a 24 hour period.
| Arm | Type | Description |
|---|---|---|
| Intranasal Clonazepam 2 mg | EXPERIMENTAL | - |
| Intranasal Clonazepam 3 mg | EXPERIMENTAL | - |
| Intranasal Clonazepam both Dose Groups 2 mg & 3 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Clonazepam | DRUG | 1 Dose |
Inclusion Criteria: * Diagnosis of refractory epilepsy * No Nasal conditions that would preclude the use of intranasal product Exclusion Criteria: * Subject with a clinical significant unstable medical abnormality * Subject currently or regularly taking Clonazepam
Top 9 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | XENE | 4 | PHASE3 | Azetukalner |
| Praxis Precision Medicines, Inc. | PRAX | 5 | PHASE3 | Vormatrigine, Elsunersen |
| Rapport Therapeutics, Inc. | RAPP | 3 | PHASE3 | RAP-219 |
| Supernus Pharmaceuticals, Inc. | SUPN | 4 | PHASE2 | SPN-817, BIS-001ER |
| Biohaven Ltd. | BHVN | 3 | PHASE2 | BHV-7000 |
| Harmony Biosciences Holdings, Inc. | HRMY | 1 | PHASE3 | Clemizole |
| Jazz Pharmaceuticals Public Limited Company | JAZZ | 3 | PHASE1 | CBD-OS, Epidiolex |
| Bright Minds Biosciences Inc. | DRUG | 1 | PHASE2 | BMB-101 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-260 |
Clonazepam is being studied as a treatment for epileptic seizures in adults. It is an investigational small molecule developed by Jazz Pharmaceuticals plc under the ticker JAZZ. The clinical program has focused on an intranasal formulation tested in adult subjects aged 18 years and older with epilepsy.
Clonazepam is a positive allosteric modulator that targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. By acting on these subunits, it modulates GABA-A receptor activity, which is the receptor class associated with inhibitory signaling in the central nervous system relevant to seizure control.
Jazz Pharmaceuticals plc, which trades under the ticker JAZZ, is the developer of Clonazepam for epilepsy. The company is advancing the intranasal formulation of this small molecule as part of its neurology pipeline.
Clonazepam is in Phase 2 development for epilepsy. The program includes one completed Phase 2 trial, and there are currently no active trials listed. It is an investigational therapy and is not described as approved for this indication.
Clonazepam has been evaluated in the Phase 2 trial NCT00594945, titled Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures. The trial enrolled 45 adults, was controlled, and was conducted in the United States and Finland. It is now completed.